Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of EC-18 in Healthy Subjects
NCT02496143Phase 1Completed
- Sponsor
- Enzychem Lifesciences
- Start
- Jul 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mosedipimod in chemotherapy-induced neutropenia (CIN) (4 cohorts), sponsored by Enzychem Lifesciences. Primary endpoint: Treatment Emergent Adverse Events at 30 days. Started Jul 2015; status: completed.
02
Drugs
mosedipimod
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT02496143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496143.